Evidence map›Paper›PMID 40437330›Full record

ArticleEuropean journal of nutrition2025

Dietary glucosamine supplement use and lower surgery risk in individuals with inflammatory bowel disease: a prospective Cohort Study.

Jiawei Geng, Xuejie Chen, Sidan Wang, Lintao Dan, Qijia Gong, Jie Chen, Xiaoyan Wang, Xiaocang Cao, Zhongyan Du

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jiawei Geng *Department of Gastroenterology, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Xuejie Chen *Department of Gastroenterology, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Sidan Wang *Department of Gastroenterology, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Lintao DanDepartment of Gastroenterology, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Qijia GongDepartment of Gastroenterology, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Jie ChenDepartment of Gastroenterology, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Xiaoyan WangDepartment of Gastroenterology, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China. wangxiaoyan@csu.edu.cn.ORCID http://orcid.org/0000-0002-7281-1078
Xiaocang CaoDepartment of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Tianjin, China. doccaoxc@163.com.
Zhongyan DuSchool of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China. duzhongyan@zcmu.edu.cn.

Funding

Creative Research Groups of the Natural Science Foundation 2024JJ1014National Natural Science Foundation of China 82004353National Natural Science Foundation of China 8217033803National Natural Science Foundation of China 82170553National Natural Science Foundation of China U23A20492
6 · The paper itself

Abstract

purposeWe aim to evaluate the association between the use of glucosamine, a widely used dietary supplement, and the risk of IBD-related surgery in a prospective cohort study.

methodsWe leveraged data from 6059 individuals with IBD from the UK Biobank. Habitual use, frequency of use, and the dose of glucosamine were evaluated using self-reported records, multiple rounds of dietary recall, and prescription information from primary care data, respectively. IBD-related surgery was identified through inpatient data. Cox proportional-hazard model and logistic regression model were applied to examine the associations.

resultsDuring a mean follow-up of 12.2 years, we documented 684 incident IBD-related surgery events. Compared with non-users, habitual glucosamine users presented (66.6 vs 97.1 cases/10,000 person-years, HR 0.73, 95% CI 0.58-0.92, P = 0.009) lowered risk of IBD-related surgery, decreased risk in Crohn's disease (80.6 vs 131.0 cases/10,000 person-years, HR 0.60, 95% CI 0.41-0.89, P = 0.011), while it was not significant in ulcerative colitis (61.1 vs 79.5 cases/10,000 person-years, HR 0.88, 95% CI 0.65-1.18, P = 0.386). The risks of IBD-related surgery were also lower among occasional users (HR 0.34, 95% CI 0.15-0.77, P = 0.010) and constant users (HR 0.48, 95% CI 0.25-0.90, P = 0.022) than non-users. For those using prescribed glucosamine, a higher prescription dose was associated with a lower risk of related surgery (OR 0.15, 95% CI 0.02-0.86, P = 0.034).

conclusionUse of glucosamine, as a safe dietary supplement, is associated with a lower risk of IBD-related surgery, which would be a promising strategy in IBD management.

Indexed as

Dietary SupplementsGlucosamineInflammatory Bowel DiseasesAdultAgedColitis, UlcerativeFemaleHumansMaleMiddle AgedProspective StudiesRisk FactorsUnited KingdomGlucosamineClinical outcomesDietary supplementsGlucosamineInflammatory bowel diseaseSurgery

Identifiers

PMID40437330

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.